[Form 4] MetLife, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Laura J. Hay, a director of MetLife, Inc. (MET) reported a non-derivative acquisition of 26 shares of MetLife common stock executed on 09/09/2025 at a reported price of $79.29 per share. After the transaction she is shown as beneficially owning 3,727 shares directly. The filing states this transaction reflects the imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning shares that became payable were deferred and recorded as additional common stock.

This disclosure is routine for director deferred compensation arrangements and documents a small, internal equity accrual rather than an open-market purchase or sale.

Insights

Securities Analyst

TL;DR: Small, routine dividend reinvestment increased a director's direct holdings by 26 shares to 3,727 shares.

This Form 4 reports an internal imputed dividend reinvestment under MetLife's non-management director deferred compensation plan. The transaction size (26 shares at $79.29) is immaterial relative to company float and does not indicate a market signal. It documents compliance with Section 16 reporting requirements and provides transparency on director equity accumulation through plan mechanics rather than discretionary trading.

Corporate Governance Expert

TL;DR: Administrative recording of deferred-share reinvestment for a director; governance disclosure appears routine and complete.

The filing identifies the reporting person as a director and specifies the nature of the ownership change as imputed reinvestment of dividends on deferred shares. This aligns with standard deferred compensation practices for non-management directors and fulfills insider-reporting obligations. There is no indication of a new grant, exercise, or cash-market transaction; the filing documents a plan-driven accrual.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hay Laura J

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		26	A	$79.29	3,727	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Laura J. Hay report on Form 4 for MET?

The Form 4 reports an acquisition of 26 shares of MetLife common stock recorded as an imputed dividend reinvestment under the director deferred compensation plan.

When was the transaction and at what price per share?

The transaction date is listed as 09/09/2025 with a reported price of $79.29 per share.

How many MetLife shares does Laura J. Hay beneficially own after this transaction?

Following the reported transaction she beneficially owns 3,727 shares directly.

What is the stated reason for the share acquisition?

The filing explains it is an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Does this Form 4 reflect a market purchase or sale?

No. The filing indicates the transaction resulted from a plan-driven dividend reinvestment, not an open-market trade.